Evidence map›Paper›PMID 40270973›Full record

ArticleFrontiers in immunology2025

Case Report: Rapid response to gemtuzumab-ozogamicin in a pediatric patient with refractory systemic mastocytosis with AML1::ETO+ acute myeloid leukemia.

Song Xue, Man Chen, Hui-Peng Sun, Tong Wang, Li-Na Zhang, Xing-Yu Cao

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Song Xue *Department of Bone Marrow Transplant, Beijing Lu Daopei Hospital, Beijing, China.
Man Chen *Division of Pathology & Laboratory Medicine, Beijing Lu Daopei Hospital, Beijing, China.
Hui-Peng SunDivision of Pathology & Laboratory Medicine, Beijing Lu Daopei Hospital, Beijing, China.
Tong WangDepartment of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Li-Na ZhangDivision of Pathology & Laboratory Medicine, Beijing Lu Daopei Hospital, Beijing, China.
Xing-Yu CaoDepartment of Bone Marrow Transplant, Hebei Yanda Lu Daopei Hospital, Langfang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This article describes a 6-year-old patient diagnosed with "systemic mastocytosis with AML1::ETO+ AML", he experience refractory disease during the course of treatment and salvage treatment was ineffective. The patient was administered gemtuzumab-ozogamicin therapy, resulting in rapid remission.

Indexed as

Core Binding Factor Alpha 2 SubunitGemtuzumabLeukemia, Myeloid, AcuteMastocytosis, SystemicOncogene Proteins, FusionRUNX1 Translocation Partner 1 ProteinAntineoplastic Combined Chemotherapy ProtocolsChildHumansMaleTreatment OutcomeAML1-ETO fusion protein, humanCore Binding Factor Alpha 2 SubunitGemtuzumabOncogene Proteins, FusionRUNX1 Translocation Partner 1 Proteinacute myeloid leukemiaAML1::ETOgemtuzumab-ozogamicin.systemic mastocytosis (SM)systemic mastocytosis with an associated hematological neoplasm

Identifiers

PMID40270973
PMCPMC12014624

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.